Samjin Pharmaceuticals Co., Ltd.

KRX:005500.KS

17280 (KRW) • At close November 12, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

20232022202120202019201820172016201520142013201220112010200920082007
Revenue 292,128.534274,031.808250,070.356235,164.889241,926.177260,016.571245,271.928239,312.894216,511.472201,305.29192,006.713185,702.08201,756.104200,410.515165,388.711147,996.742137,112.663
Cost of Revenue 146,236.922156,297.385132,238.372124,648.844121,212.525117,237.366109,290.239109,965.95496,672.60289,313.97575,040.5577,519.87180,316.01379,878.96269,268.94556,259.13850,829.288
Gross Profit 145,891.612117,734.423117,831.983110,516.045120,713.652142,779.206135,981.689129,346.94119,838.869111,991.315116,966.163108,182.209121,440.091120,531.55396,119.76691,737.60486,283.375
Gross Profit Ratio 0.4990.430.4710.470.4990.5490.5540.540.5530.5560.6090.5830.6020.6010.5810.620.629
Reseach & Development Expenses 35,430.4493,657.7642,581.9281,507.1952,601.7993,743.9583,645.5562,798.692,769.983,293.5347,619.45311,029.89210,425.0548,776.3146,121.7914,020.7163,065.228
General & Administrative Expenses 15,149.72717,144.90515,053.77113,955.10913,444.23919,703.4521,630.63722,218.78923,472.23422,623.71523,454.13623,426.59222,116.94919,700.48919,731.91619,173.31117,506.87
Selling & Marketing Expenses 26,313.19425,565.40519,708.9419,067.03115,155.10620,079.10824,077.29624,209.58522,503.4221,094.05620,991.78624,136.22332,570.8636,712.55231,823.4430,423.30925,882.752
SG&A 90,323.60242,710.3134,762.71133,022.1428,599.34539,782.55845,707.93346,428.37445,975.65443,717.77144,445.92247,562.81554,687.80956,413.04151,555.35649,596.6243,389.622
Other Expenses -639.20548,182.02746,575.91843,744.70244,615.90490.759-392.101-292.587-90.114-127.687161.468-777.84932,326.422-79.631-587.075-1,243.335-2,967.356
Operating Expenses 126,393.25694,550.10183,920.55778,274.03775,817.04883,237.589,035.14987,288.84383,873.26880,414.47186,872.26290,864.56797,439.28598,451.26184,119.40979,161.15369,571.936
Operating Income 19,498.35523,184.32233,911.42632,242.00822,205.29759,541.70546,946.5442,058.09735,965.60131,576.84430,093.917,317.64223,906.67322,080.29412,000.3612,576.45116,711.439
Operating Income Ratio 0.0670.0850.1360.1370.0920.2290.1910.1760.1660.1570.1570.0930.1180.110.0730.0850.122
Total Other Income Expenses Net -3,901.712,041.929999.813587.62-333.668508.466-474.115-3,113.897-1,370.882-1,420.694-1,470.592-2,256.783-2,143.966-6,427.53-2,076.337-2,785.644-4,145.14
Income Before Tax 15,596.64625,226.25134,911.23932,829.62821,871.62960,050.17246,472.42538,944.234,594.71930,156.1528,623.30815,060.85921,856.83915,652.7629,924.029,790.80712,566.299
Income Before Tax Ratio 0.0530.0920.140.140.090.2310.1890.1630.160.150.1490.0810.1080.0780.060.0660.092
Income Tax Expense -3,348.6493,325.3326,507.0834,950.329,990.87234,523.98610,676.68,769.8697,551.5489,439.43220,745.1154,422.41614,794.3765,175.5662,879.0463,058.9926,131.696
Net Income 18,905.78421,893.83628,404.15627,879.30811,880.75725,526.18535,795.82530,174.33227,043.17120,716.7187,878.19410,638.4437,062.46410,477.1957,044.9746,731.8156,434.603
Net Income Ratio 0.0650.080.1140.1190.0490.0980.1460.1260.1250.1030.0410.0570.0350.0520.0430.0450.047
EPS 1,459.661,727.822,308.752,266.09917.072,075.292,8912,4232,1721,664627817542817548.87525.07496.85
EPS Diluted 1,459.661,727.822,308.752,266.09917.072,075.292,8912,4232,1721,664627817542817548.87525.07496.85
EBITDA 36,111.11133,821.84141,620.37139,335.2328,677.09666,508.0253,413.63148,922.95242,671.51737,898.2635,968.12620,939.18427,575.48526,271.72215,267.26314,832.02216,771.059
EBITDA Ratio 0.1240.1230.1660.1670.1190.2560.2180.2040.1970.1880.1870.1130.1370.1310.0920.10.122